Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices
18 sept. 2024 08h00 HE
|
Elutia Inc.
EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model SILVER SPRING, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Elutia...
Elutia Celebrates First Year
06 sept. 2024 16h23 HE
|
Elutia Inc.
Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer...
Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
05 sept. 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever...
Elutia to Participate in Upcoming Investor Conferences
03 sept. 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief...
Elutia Announces Second Quarter 2024 Results
07 août 2024 16h05 HE
|
Elutia Inc.
Launch Production of EluPro® Underway, Commercial Team Expansion Continues, Financial Position SolidifiedSILVER SPRING, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or...
Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds
01 août 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced that it had received gross...
Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations
31 juil. 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA...
Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
30 juil. 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced that it will release its...
Elutia to Present at the Emerging Growth Conference on Thursday, July 18
11 juil. 2024 16h05 HE
|
Elutia Inc.
SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief...
Elutia Announces $13.26 Million Registered Direct Offering
17 juin 2024 08h01 HE
|
Elutia Inc.
SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the...